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Summary
Prior to a joint meeting of the Neurodiab Association and International Sym-
posium on Diabetic Neuropathy held in Toronto, Ontario, Canada, 13-18
October 2009, Solomon Tesfaye, Sheffield, UK, convened a panel of neuro-
muscular experts to provide an update on polyneuropathies associated with
diabetes (Toronto Consensus Panels on DPNs, 2009). Herein, we provide def-
initions of typical and atypical diabetic polyneuropathies (DPNs), diagnostic
criteria, and approaches to diagnose sensorimotor polyneuropathy as well
as to estimate severity. Diabetic sensorimotor polyneuropathy (DSPN), or
typical DPN, usually develops on long-standing hyperglycaemia, consequent
metabolic derangements and microvessel alterations. It is frequently associ-
ated with microvessel retinal and kidney disease – but other causes must be
excluded. By contrast, atypical DPNs are intercurrent painful and autonomic
small-fibre polyneuropathies. Recognizing that there is a need to detect and
estimate severity of DSPN validly and reproducibly, we define subclinical
DSPN using nerve conduction criteria and define possible, probable, and
confirmed clinical levels of DSPN. For conduct of epidemiologic surveys and
randomized controlled trials, it is necessary to pre-specify which attributes
of nerve conduction are to be used, the criterion for diagnosis, reference val-
ues, correction for applicable variables, and the specific criterion for DSPN.
Herein, we provide the performance characteristics of several criteria for the
diagnosis of sensorimotor polyneuropathy in healthy subject- and diabetic
subject cohorts. Also outlined here are staged and continuous approaches to
estimate severity of DSPN. Copyright  2011 John Wiley & Sons, Ltd.
Keywords diabetic polyneuropathy; diabetic sensorimotor polyneuropathy;
atypical diabetic polyneuropathy; classification; definitions
Abbreviations: DPN – diabetic polyneuropathy; DSPN – diabetic sensorimo-
tor polyneuropathy; MNCV – motor nerve conduction velocity; NIS – Neuro-
pathy Impairment Score.
Introduction and objectives
A summary of this, and the other updates reported here, has been published
earlier [1]. This update begins with the consideration of classification of
diabetic polyneuropathies (DPNs) and then provides definitions, minimal
criteria for diagnoses, and estimation of severity of typical DPN, i.e.
diabetic sensorimotor polyneuropathy (DSPN). Subsequently, atypical DPN
is described and discussed only briefly. This update alludes only briefly to
focal and multifocal varieties.




The neuropathies developing in patients with diabetes
mellitus are known to be heterogeneous by their
symptoms, pattern of neurological involvement, course,
risk covariates, pathological alterations, and underlying
mechanisms [2–4]. We accept the Thomas et al. [5,6] and
Boulton et al. [7,8] separation of DPNs into generalized
polyneuropathies (DPNs) and focal (e.g. CrIII neuropathy
and median neuropathy at the wrist from carpal
tunnel syndrome) and multifocal varieties (e.g. multiple
mononeuropathy, lumbosacral, thoracic, and cervical
radiculoplexus neuropathies [5–9]). It is known that all
patterns of neuropathy listed above also occur in patients
without diabetes mellitus [10].
The evidence that generalized DPNs can be further clas-
sified into at least two major subgroups (typical and atyp-
ical) seems compelling [5–8]. Typical DPN is a chronic,
symmetrical, length-dependent sensorimotor polyneu-
ropathy and is thought to be the commonest variety of
DPN, from cohort and population-based epidemiological
studies [3]. It develops on a background of long-standing
chronic hyperglycaemia, associated metabolic derange-
ments, and cardiovascular risk factors [11–17]. It is
postulated that metabolic derangements, secondary to
chronic hyperglycaemia (polyol shunting, accumulation
of advanced glycation end products, oxidative stress,
lipid abnormalities among other metabolic derange-
ments [17–20], and microvessel alterations [21–23]),
are involved in the development of DSPN. The patho-
logical alterations of microvessels are similar to those
observed in diabetic retinopathy and nephropathy. In
cross-sectional and longitudinal epidemiological surveys
of population-based cohorts of patients with diabetes
mellitus, total hyperglycaemia has been shown to be an
important risk covariate [14,16], but vascular risk factors
have been emphasized in other studies [13,15]. Progres-
sion of DSPN has been shown to be prevented or inhibited
by rigorous glycaemic control [11,12,24,25]. DSPN has
been found to be statistically associated with retinopathy
and nephropathy [3,26].
Atypical DPNs are different from DSPN in several impor-
tant features, i.e. onset, course, manifestations, associa-
tions, and perhaps putative mechanisms [5–8,27–31].
They appear to be intercurrent varieties, developing at
any time during the course of a patient’s diabetes mellitus
[30–32]. Onset of symptoms may be acute, subacute, or
chronic, but the course is usually monophasic or fluctu-
ating over time. Archer et al. [30] described a prototypic
variety quite distinct from the usual course of DSPN.
Their nine cases had painful neuropathies that were
preceded by weight loss, a feature emphasized by Ellen-
berg [29] but also characteristic of diabetic lumbosacral
radiculoplexus neuropathy [9]. Burning pain and con-
tact hyperalgesia were typical features. Sensory loss was
mild and there was no or little weakness. With conven-
tional treatment they improved. Symptoms disappeared in
months. Retinopathy or nephropathy was not observed.
Nerve conduction abnormalities, if present, were mild.
Younger et al. [31] biopsied cutaneous nerves of patients
having some features of the Archer et al. patients. They
reported lymphocytic infiltrates, albeit small, but pos-
sibly suggestive of an inflammatory (perhaps immune)
pathogenesis. It is important to note that many of these
patients developed their symptomatic sensory and auto-
nomic polyneuropathies shortly after rigorous control of
hyperglycaemia had been achieved, making it unlikely
that chronic hyperglycaemia is a putative risk covari-
ate – different from the causative factors of typical DSPN.
Investigators have described an increased prevalence
of IFG or IGT in patients with small-fibre painful
polyneuropathies [33–38]. Whether IFG or IGT causes
an increased prevalence of DPN, and if it does, whether it
causes typical or atypical DPN remains unsettled [34–42]
for methodological reasons and contradictory results [39].
The focal and multifocal neuropathies associated with
diabetes mellitus can be broadly subdivided into those in
which repeated, mild, mechanical trauma, compression,
or entrapment is causative and others possibly related to
inflammation with or without associated ischaemia. The
first group includes median neuropathy at the wrist, ulnar
neuropathy at the elbow, and peroneal neuropathy at the
knee. The second group may include mononeuropathy,
e.g. cranial nerve III and multiple mononeuropathies,
and radiculoplexus neuropathies of the lumbosacral (also
called diabetic amyotrophy, Bruns Garland syndrome, and
by other names), thoracic, and cervical segments. There
is increasing evidence that inflammation, microvasculitis,
and ischaemia are involved in these radiculoplexus
neuropathies [9,43–46].
Typical DPN (i.e. diabetic
sensorimotor polyneuropathy)
The San Antonio Conference defined DPN as ‘peripheral
or autonomic nerve damage attributable solely to diabetes
mellitus’ [47]. Boulton et al. [7] defined DPN as ‘presence
of symptoms and/or signs of peripheral nerve dysfunction
in people with diabetes after exclusion of other causes’.
The case definition of distal symmetric polyneuropathy
(of which DSPN is a member) from the AAN, AAEM,
and AAPMR report, and based on a formal review of the
medical literature, states that ‘the highest likelihood of
polyneuropathy occurs with a combination of neuropathic
symptoms, multiple signs, and abnormal electrodiagnostic
studies’ [48]. Whereas each of these definitions seems
acceptable and intuitively correct, they do not separate
typical DPN (i.e. DSPN) from atypical DPN, which we
judge to be needed. Here, we also emphasize more precise
nerve conduction abnormality criteria for subclinical
DSPN (Stage 1a) and provide approaches useful for
estimating the severity of DSPN. In addition, proficiency
of the clinical examination of signs and symptoms and of
nerve conduction testing is emphasized.
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We propose separate definitions for typical DPN
(DSPN) and atypical DPN. DSPN is a symmetrical length-
dependent sensorimotor polyneuropathy attributable to
chronic hyperglycaemia, associated metabolic derange-
ments, cardiovascular risk covariates, and microvessel
alterations. An abnormality of nerve conduction which
may be subclinical (asymptomatic and without signs or
symptoms of polyneuropathy) appears to be the first
objective and quantitative indication of DSPN and is a
necessary condition for the confirmed diagnosis of DSPN.
The occurrence of diabetic retinopathy and nephropathy
in a given patient strengthens the case that a patient’s
sensorimotor polyneuropathy is attributable to diabetes
mellitus. However, the association among these complica-
tions is not strong enough to allow diagnosis of DSPN from
knowing that diabetic retinopathy or nephropathy occurs
in the same patient, i.e. other causes of polyneuropathy
must be excluded.
For epidemiological surveys or controlled clinical tri-
als of DSPN, we advocate the use of nerve conduction
as an early and reliable indication of the occurrence of
subclinical DSPN. To be reliable as the indicator of sub-
clinical DSPN (Stage 1a), nerve conduction evaluation
must be carried out rigorously using appropriate testing
conditions and techniques using suitable criteria and ref-
erence values corrected for applicable variables of age,
gender, height, and weight – the topic discussed in the
next section. Volunteered symptoms and elicited signs are
needed to confirm the diagnosis and to estimate severity.
Other neurophysiological tests (e.g. quantitative sensa-
tion and autonomic tests) are useful in characterizing
neuropathic expression. As for nerve conduction evalu-
ations, so also for the clinical evaluation of signs and
symptoms, careful attention needs to be given to the
issue of proficiency of examiners. In a recent study of
the proficiency of neuromuscular experts as compared to
their 75% group diagnosis or as compared to confirmed
nerve conduction abnormality, their diagnoses were more
variable and less reproducible than usually assumed or
desirable – indicating a need for careful instruction, con-
sensus development, and quality assurance of the clinical
evaluation, in conducting epidemiological surveys or ran-
domized controlled clinical trials [49–51]. In an earlier
but smaller study assessing proficiency with agreement
on methods of examination and diagnosis and using
confirmed nerve conduction abnormality as a guide in
training, high levels of concordance among clinical exam-
inations were achieved [52].
Atypical DPNs
Atypical DPN has not been as well characterized and
studied as has typical DPNs (i.e. DSPN). It is possible
that atypical DPN is actually not a single entity but sev-
eral varieties. This condition appears to be an intercurrent
and monophasic or fluctuating disorder, tending to prefer-
entially involve small sensory and autonomic nerve fibres,
by not being closely associated with chronic hypergly-
caemia or associated with the microvessel abnormalities
found in DSPN.
Abnormality of nerve conduction
as minimal criteria for the diagnosis
of subclinical DSPN
The evidence that nerve conduction abnormality of limb
nerves is the most objective and quantitative indication
of DSPN comes from studies of DPN cohorts [53–57] and
population-based study of healthy subject and diabetes
mellitus cohorts [52,58–61].
For purposes of using nerve conduction studies for the
research diagnosis of subclinical DSPN (Stage 1a), it is
necessary that they are performed proficiently, using suit-
able criteria for abnormality based on adequately obtained
reference values corrected for applicable variables and
that the results are clearly presented and interpreted.
In performance of nerve conduction studies, particular
attention needs to be given to adequate maintenance of
limb temperature, correct and exact placement of stim-
ulating and recording electrodes, accurate measurement
of distances, use of just supramaximal electrical stimula-
tion, recognition of normal anatomic variations (e.g. nerve
crossovers), avoidance of recording of spurious responses,
and adequate documentation and record keeping. Assum-
ing that nerve conduction values have been proficiently
assessed, it is then necessary to express abnormality by
comparison with adequately obtained reference values
and to use these values to determine whether DSPN is
present based on appropriate criteria for its diagnosis – the
subject explored further in subsequent paragraphs.
The nerve conduction criteria, which might be used for
the diagnosis of DSPN in epidemiological surveys, ran-
domized controlled trials, and even for medical practice,
were recently assessed in databases of previously studied
healthy subjects and a population-based cohort of diabetic
subjects (RDNS) – cohorts from Olmsted County, MN,
USA [3,16,58]. Ideal nerve conduction criteria for DSPN
would use attributes representative of neurophysiological
abnormality in DSPN employing attributes that are fre-
quently abnormal in the condition. In an HS cohort, use of
the criterion should result in low frequency of abnormal-
ity, i.e. few false positives, providing values of abnormality
near the set percentile abnormality, e.g. 2.5th or 1st per-
centile. In a population-representative cohort of patients
with diabetes mellitus, the criterion should sensitively
detect DSPN – in perhaps one third or more of the cases.
In the Nerve Conduction Criteria Study, the authors were
especially concerned about the frequency of false positives
(type 1 error) because multiple attributes and multiple
nerves are usually assessed in nerve conduction studies.
The Nerve Conduction Criteria Study [62] evaluated
eight nerve conduction criteria for the potential diagnosis
of DSPN and the frequencies of abnormalities were tabu-
lated in the HS and diabetic subject cohorts. In the diabetic
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Table 1. Nerve conduction abnormality in the RDNS and RDNS-HS cohorts using different criteria
RDNS-HSa (N = 330) RDNS (N = 456)
No. (%) abnormal Prevalence at first visit
5th/95th 2.5th/97.5th 1st/99th 2.5th/97.5th 1st/99th
Criteria 1: ≥1 of 12 nerve conduction
attributes abnormalb
123 (37.3) 57 (17.3) 30 (9.1) 60.1 42.5
Criteria 2: ≥1 abnormal in 2 separate
nerves
37 (11.2) 8 (2.4) 3 (0.9) 34.6 22.1
Criteria 3: ≥1 abnormal in 2 separate
nerves (1 is sural)
24 (7.3) 7 (2.1) 2 (0.6) 26.3 15.6
Criteria 4: Peroneal CV abnormal and
sural amplitude abnormal
2 (0.6) 2 (0.6) 1 (0.3) 11.8 3.9
Criteria 5:  2 nerve conduction
normal deviates abnormal (peroneal
CV and sural amplitude)
17 (5.2) 9 (2.7) 4 (1.2) 37.9 31.1
Criteria 6:  2 nerve conduction
normal deviates abnormal (peroneal
CV and tibial CV)
17 (5.2) 9 (2.7) 4 (1.2) 34.2 21.1
Criteria 7:  5 nerve conduction
normal deviates abnormal
17 (5.2) 9 (2.7) 1 (0.3) 28.3 17.5
Criteria 8:  6 nerve conduction
normal deviates abnormal
17 (5.2) 9 (2.7) 4 (1.2) 30.9 23.5
aOn the basis of theoretical considerations (Bonferonni’s modelling) the following abnormal frequencies would be expected based
on type 1 error and lack of linkage among attributes studied.
bOf 330 × 12 = 3960 nerve attributes tested, 197 (5.0%) are abnormal at the 95th, 75 (1.9%) at the 97.5th and 36 (0.9%) at the
99th.
subject cohort, the frequencies of nerve conduction abnor-
mality using 2.5th/97.5th cut-offs were peroneal motor
nerve conduction velocity (MNCV), 26.3%; sural ampli-
tude, 25.4%; tibial MNCV, 24.8%; ulnar MNCV, 21.3%;
peroneal F-latency, 16.9%; and ulnar F-latency, 16.0%.
Among the pairs of these six nerve conduction attributes,
there was highly significant agreement for the diagnosis
of DSPN.
Eight criteria for DSPN were compared (Table 1). Cri-
terion 1 – ‘≥1 abnormality of any one attribute from any
nerve’ – did not perform well. It was inadequate in the
following respects. Abnormality could be due to mononeu-
ropathy. Use of this criterion resulted in an excessive
number of false-positive diagnoses. In the HS cohort
(expected to have no patients with DSPN) and using this
criterion and percentiles of ≤5th/≥95th, ≤2.5th/≥97.5th,
and ≤1st/≥99th, abnormality frequencies of 37.3, 17.3,
and 9.1% resulted – a large type 1 error. Assuming speci-
ficity to be the same for the diabetic as they were for
HS (a reasonable assumption because the technique of
testing and references values were the same), this crite-
rion produced too high a frequency of abnormality among
diabetic patients (Table 1).
Criterion 2 – ‘≥1 abnormal attributes in ≥2 separate
nerves tested’. Inspection of the table shows that this
criterion performs much better than Criterion 1. Using
the ≤5th/≥95th percentile cut-off, the false positives are
probably excessively high in both the HS and the diabetic
subjects, but using lower percentile abnormality the error
rate is acceptable. Criterion 3 – ‘an abnormality ≤1st/99th
percentile of any attribute of two separate nerves, one
of which must be the sural nerve’ (AAN, AAEM, and
AAPMR). Using the ≤5th/≥95th percentile this criterion
results in excessive false positives among HS and using
the ≤1st/≥95th criteria in the diabetic subjects, too low a
frequency of DSPN is obtained. Criterion 4 – ‘abnormality
of peroneal MNCV and sural amplitude’. Use of this
criterion results in low sensitivity in both healthy subject
and diabetes mellitus cohorts (Table 1). Criteria 5–8 are
composite scores of nerve conduction attributes (Table 1).
Irrespective of which composite score was used, specificity
was close to the preset percentile abnormality level in the
HS cohort. In the diabetic subject cohort, good specificity
and sensitivity were achieved, especially for  2 nerve
conduction normal deviates ≥97.5th, i.e. peroneal MNCV
and sural amplitude.
From the results of the Nerve Conduction Criteria
Study, the authors concluded that composite sum scores of
normal deviates (from percentiles) and nerve conduction
attributes performed best for diagnosing DSPN, although
performance of Criterion 2, ‘≥1 abnormal attribute in ≥2
separate nerves’, and Criterion 3 (when modified) was
also acceptable. In clinical practice, less rigid criteria may
be justified (Table 1, footnote a).
Estimating severity of DSPN
For medical practice and for conducting epidemiological
surveys and randomized controlled clinical trials, mea-
surement of the severity of DSPN in a given patient is
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needed to estimate severity of symptoms, signs, neuro-
physiological test results, and overall severity of DSPN.
This need is not met by simply tallying patients as having,
or not having, DSPN – severity also needs to be ascer-
tained. Two approaches have been described – staged [63]
and continuous measurement approaches [64].
The staged approach
Stage 0 = criteria for subclinical DSPN have not been
met – an abnormality of nerve conduction not being
present.
Stage 1a = criteria for subclinical DSPN have been met,
but the patient does not have signs or symptoms of DSPN.
If Criterion 3 (from previous sections) for DSPN is chosen,
sural amplitude must be ≤1st percentile and any one other
nerve conduction attribute assessed is ≤1st or ≥99th
percentile with corrections made for applicable variables.
If one of the composite scores is used (Criterion 5–8),
the composite normal deviate score must be ≥97.5th or
≥99th percentile – whichever is chosen.
Stage 1b = criteria for subclinical neuropathy have been
met and neuropathic signs without neuropathic symptoms
are present.
Stage 2a = criteria for subclinical neuropathy have been
met and the patient has neuropathic symptoms with or
without neuropathic signs.
Stage 2b = criteria for subclinical neuropathy have
been met and patient has unequivocal weakness of ankle
dorsiflexion (Table 1, footnote a).
Continuous measurement
of the severity of DSPN
An alternative method to assess the severity of DSPN is
to use a continuous measure of neuropathic signs without
or with nerve conduction or other neurophysiological
test abnormalities. The Neuropathy Impairment Score
(NIS) and NIS of the lower limb provide a sum score
of scored weakness of a predetermined list of muscle
groups, scored decrease of muscle stretch reflexes, and
scored abnormality of sensory modalities of sensation of
fingers and toes. Judgements are to be corrected for the
influence of age, gender, anthropomorphic variables, and
physical fitness. The NIS or NIS of the lower limb scores
have been extensively described [65] and extensively
used in epidemiological surveys and therapeutic trials
of chronic inflammatory demyelinating and monoclonal
gammopathies of undetermined significance neuropathies
[52,66] and also in DSPN [65,67]. Paper and electronic
forms of NIS and symptoms and disability scores have
been extensively used in epidemiological surveys and
randomized controlled clinical trials [68]. With some
modifications, the MRC scale has been used to score
overall muscle weakness [69]. Several other sum scores
of impairment have been developed and published. The
symptoms (and in some cases signs) of DSPN can be
scored using the Neuropathy Symptoms Score [70],
Neuropathy Symptoms and Change [68], the Michigan
Score [71], and the Toronto Clinical Neuropathy Score
[72–74].
Composite scores of representative attributes of nerve
conduction have also been shown to be useful in
estimating the severity of polyneuropathies [75–78]. It is
not possible to develop a sum score of attributes of nerve
conduction without some transformation of the data.
Composite scores of nerve conduction can be derived
if percentile values are expressed as normal deviates
from percentiles corrected for applicable variables and
abnormality is expressed in the same tail of the normal
distribution. A composite score of neurophysiological
tests is especially useful in epidemiological surveys
and randomized controlled trials. Because DSPN is
the summation of different symptoms, signs, and test
abnormalities, use of composite normal deviate scores
allows combining representative signs and test results.
A further important use of composite scores is that it
allows assessment of change in severity even within the
range of normal and extending into abnormality. The
percentile position of this composite measure must be
independently set by studies of the composite score in
reference populations. An example of such a composite
score for use in DSPN is  5 nerve conduction normal
deviates. The  5 nerve conduction normal deviate
score is made up of peroneal nerve velocity, amplitude,
distal latency, tibial distal latency, and sural amplitude,
with the five nerve conduction attributes expressed as
normal deviates. In a similar manner, it is possible to
add other neurophysiological measures to the composite
nerve conduction score. In  7 NTs normal deviate, 
5 nerve conduction normal deviate is added to by the
normal deviate score of vibratory detection threshold of
the toes and heart rate deep breathing decrease.
On the assumption that NIS abnormality correlates
with neurophysiological test abnormalities, a composite
score combining the two has been proposed and used in
epidemiological surveys and controlled trials, e.g. NIS of
the lower limb +  7 NT normal deviate score.
Conclusions
The Neurodiabetes Consensus (Toronto) Group on
DPNs supports the earlier classification of DPNs by
Thomas et al. [5,6] and Boulton et al. [7,8] into
generalized and focal and multifocal, and further
separating DPNs into typical (DSPN) and atypical DPNs.
For epidemiological surveys and controlled trials, we
define DSPN as chronic, symmetric, length-dependent
sensorimotor polyneuropathy developing from metabolic
derangements and microvessel alterations related to
chronic hyperglycaemia and cardiovascular risk factors.
Metabolic derangements and microvessel alterations
appear to be similar and common to those of retinopathy
and nephropathy. As the pattern of DSPN is not unique in
diabetes mellitus, other causes need to be excluded.
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Figure 1. Minimal criteria for diabetic polyneuropathy
Atypical DPN are intercurrent generalized polyneu-
ropathies having an acute or subacute onset and a
monophasic or relapsing course that may develop at any
time during a patient’s diabetes mellitus. These atypical
neuropathies need further studies emphasizing natural
history, classification, and outcome. Like DSPN, so also
in atypical DPN other causes of neuropathy need to be
excluded.
Definitions of minimal criteria
for DSPN
1. Possible Clinical DSPN
Symptoms or signs of DSPN. Symptoms may
include: decreased sensation, positive neuropathic
sensory symptoms (e.g. ‘asleep numbness’, ‘prick-
ling’ or ‘stabbing’, ‘burning’ or ‘aching’ pain) pre-
dominantly in the toes, feet, or legs. Signs may
include: symmetric decrease of distal sensation or
unequivocally decreased or absent ankle reflexes.
2. Probable Clinical DSPN
A combination of symptoms and signs of distal
sensorimotor polyneuropathy with any two or more
of the following: neuropathic symptoms, decreased
distal sensation, or unequivocally decreased or
absent ankle reflexes.
3. Confirmed Clinical DSPN
An abnormal nerve conduction study and a
symptom or symptoms or a sign or signs of
sensorimotor polyneuropathy. Severity of DSPN can
be assessed by staged or continuous approaches
described above and by dysfunction and disability
scores [65].
4. Subclinical DSPN (Stage 1a)
No signs or symptoms of polyneuropathy.
Abnormal nerve conduction, as described above,
is present (Figure 1).
Atypical DPNs
Before further classification of atypical DPNs, setting
minimal criteria for diagnosis and estimating severity,
further characterization from epidemiological surveys and
mechanistic studies are needed. The issue of painful,
autonomic, and nerve morphological abnormalities are
discussed in subsequent articles.
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